On March 16, 2026, Enzon Pharmaceuticals, Inc. announced an extension to the expiration date for its exchange offer concerning the Series C Non-Convertible Redeemable Preferred Stock. The new expiration date is set for March 19, 2026, at 5:00 p.m. Eastern Time. This extension allows holders of the Series C Preferred Stock to exchange their shares for common stock of Enzon, which is valued at $0.01 per share. The company has indicated that this extension is part of its ongoing efforts to optimize its capital structure and enhance shareholder value. The press release detailing this extension has been filed as Exhibit 99.1 to the Form 8-K. Enzon's management believes that this move will provide shareholders with more flexibility and potentially improve liquidity in the market for its common stock. The company is committed to maintaining transparent communication with its investors and will continue to provide updates as necessary. Investors are encouraged to review the full details of the exchange offer and the implications it may have on their investments. The company’s filings can be accessed through the SEC’s EDGAR database.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.